8.62
-0.39 (-4.33%)
| Previous Close | 9.01 |
| Open | 9.09 |
| Volume | 1,206,976 |
| Avg. Volume (3M) | 1,001,286 |
| Market Cap | 1,323,049,344 |
| Price / Sales | 12.79 |
| Price / Book | 7.34 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 - 12 May 2025 |
| Profit Margin | -89.57% |
| Operating Margin (TTM) | 27.42% |
| Diluted EPS (TTM) | -0.700 |
| Quarterly Revenue Growth (YOY) | 188.20% |
| Total Debt/Equity (MRQ) | 11.69% |
| Current Ratio (MRQ) | 2.89 |
| Operating Cash Flow (TTM) | -151.03 M |
| Levered Free Cash Flow (TTM) | -107.84 M |
| Return on Assets (TTM) | -22.00% |
| Return on Equity (TTM) | -73.24% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Wave Life Sciences Ltd. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | -1.5 |
| Price Volatility | 1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.80 |
|
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 16.53% |
| % Held by Institutions | 83.49% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 26.00 (Jefferies, 201.62%) | Buy |
| Median | 24.00 (178.42%) | |
| Low | 22.00 (HC Wainwright & Co., 155.22%) | Buy |
| Average | 24.00 (178.42%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 10.19 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 26 Mar 2025 | 22.00 (155.22%) | Buy | 10.02 |
| 05 Mar 2025 | 22.00 (155.22%) | Buy | 10.57 | |
| Jefferies | 25 Feb 2025 | 26.00 (201.62%) | Buy | 10.36 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HENRY CHRISTIAN O | - | 9.67 | -10,500 | -101,535 |
| Aggregate Net Quantity | -10,500 | |||
| Aggregate Net Value ($) | -101,535 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 9.67 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HENRY CHRISTIAN O | Director | 20 Mar 2025 | Automatic sell (-) | 10,500 | 9.67 | 101,535 |
| HENRY CHRISTIAN O | Director | 20 Mar 2025 | Option execute | 10,500 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |